Avac Event

The Scientific Journey of Lenacapavir: From basic science to clinical development to impact

Learn how sustained US support from NIH discovery science to South Africa’s clinical research infrastructure made the development of LEN for PrEP possible. 

Speakers include:

  • Wes Sundquist (University of Utah), on the early-stage science behind capsid inhibitors
  • Linda-Gail Bekker (Desmond Tutu HIV Foundation), on the PURPOSE 1 trial in South Africa, where not a single HIV infection occurred